What is HepQuant?
HepQuant specializes in the development of non-invasive, blood-based quantitative tests designed to provide precise assessments of liver health. At the core of its product portfolio is the HepQuant DuO, a sophisticated diagnostic tool that generates a Disease Severity Index (DSI). This metric serves as a critical decision-support instrument for clinicians and drug developers, facilitating more accurate risk stratification and patient management. By moving away from traditional, invasive biopsy procedures, HepQuant is effectively transforming the standard of care in hepatology, offering a scalable solution that addresses the growing demand for objective, data-driven clinical insights in liver disease treatment.
How much funding has HepQuant raised?
HepQuant has raised a total of $341K across 2 funding rounds:
Debt
$150K
Debt
$191K
Debt (2020): $150K with participation from PPP
Debt (2021): $191K led by PPP
Key Investors in HepQuant
PPP
Public-Private Partnership
What's next for HepQuant?
With this late-stage capital, HepQuant is poised to transition into a phase of accelerated commercial expansion and clinical integration. The strategic focus will likely center on broadening the adoption of the HepQuant DuO platform among major healthcare providers and pharmaceutical entities engaged in liver disease research. As the company continues to refine its diagnostic algorithms, the emphasis will remain on enhancing the clinical utility of the DSI, thereby solidifying its role as an essential partner in the management of complex liver pathologies. Future growth trajectories suggest a continued commitment to innovation, potentially exploring new therapeutic areas where quantitative liver assessment can improve patient outcomes and reduce healthcare costs.
See full HepQuant company page
